Clinical trial · Observational
Quest for Tumour Evolution of Non-small Cell Lung Cancer
Quest for Tumour Evolution of Non-small Cell Lung Cancer in Chinese (Unicorn-Quest)
NCT05811169CI-TRIAL-00065616active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study and comprehend the evolutionary and genomic landscape between primary and metastatic sites and the dynamics of intratumour and intertumour heterogeneity over time with reference to the treatment modalities for each Chinese patient with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Next generation sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Early or metastatic non-small cell lung cancer
- description
- The formalin-fixed paraffin-embedded specimen will be retrieved for next generation sequencing.
- interventionNames
- Genetic: Next generation sequencing
Primary outcomes (2)
- measure
- Intratumour heterogeneity
- timeFrame
- 5 years
- description
- Number of participants who have single actionable and non-actionable genetic mutations and multiple actionable and non-actionable genetic mutations within the same groups of patients with early and metastatic non-small cell lung cancer
- measure
- Intertumour heterogeneity
- timeFrame
- 5 years
- description
- Number of participants who have single actionable and non-actionable genetic mutations and multiple actionable and non-actionable genetic mutations of different groups of patients with early and metastatic non-small cell lung cancer
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written Informed consent * Patients ≥18 years of age, with histologically confirmed non-squamous non-small cell lung cancer who plan to receive active anti-cancer treatment for their non-small cell lung cancer. * Sufficient tissues with a minimum of two tumour or nodal regions are available for the study based on pre-operative imaging and post-operative pathological findings. Exclusion Criteria: * Any other\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy). Any other\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\*\*. \*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer \*\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC. * Psychological condition that would preclude informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.